Cargando…

Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China

BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhongjie, Guan, Xuhua, Mao, Naiying, Luo, Huiming, Qin, Ying, He, Na, Zhu, Zhen, Yu, Jianxing, Li, Yu, Liu, Jianhua, An, Zhijie, Gao, Wenjing, Wang, Xiaoli, Sun, Xiaodong, Song, Tie, Yang, Xingfen, Wu, Ming, Wu, Xianping, Yao, Wenqing, Peng, Zhibin, Sun, Junling, Wang, Liping, Guo, Qing, Xiang, Nijuan, Liu, Jun, Zhang, Bike, Su, Xuemei, Rodewald, Lance, Li, Liming, Xu, Wenbo, Shen, Hongbing, Feng, Zijian, Gao, George F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864613/
https://www.ncbi.nlm.nih.gov/pubmed/33585828
http://dx.doi.org/10.1016/j.lanwpc.2021.100094
_version_ 1783647690602577920
author Li, Zhongjie
Guan, Xuhua
Mao, Naiying
Luo, Huiming
Qin, Ying
He, Na
Zhu, Zhen
Yu, Jianxing
Li, Yu
Liu, Jianhua
An, Zhijie
Gao, Wenjing
Wang, Xiaoli
Sun, Xiaodong
Song, Tie
Yang, Xingfen
Wu, Ming
Wu, Xianping
Yao, Wenqing
Peng, Zhibin
Sun, Junling
Wang, Liping
Guo, Qing
Xiang, Nijuan
Liu, Jun
Zhang, Bike
Su, Xuemei
Rodewald, Lance
Li, Liming
Xu, Wenbo
Shen, Hongbing
Feng, Zijian
Gao, George F
author_facet Li, Zhongjie
Guan, Xuhua
Mao, Naiying
Luo, Huiming
Qin, Ying
He, Na
Zhu, Zhen
Yu, Jianxing
Li, Yu
Liu, Jianhua
An, Zhijie
Gao, Wenjing
Wang, Xiaoli
Sun, Xiaodong
Song, Tie
Yang, Xingfen
Wu, Ming
Wu, Xianping
Yao, Wenqing
Peng, Zhibin
Sun, Junling
Wang, Liping
Guo, Qing
Xiang, Nijuan
Liu, Jun
Zhang, Bike
Su, Xuemei
Rodewald, Lance
Li, Liming
Xu, Wenbo
Shen, Hongbing
Feng, Zijian
Gao, George F
author_sort Li, Zhongjie
collection PubMed
description BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population. METHODS: We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay. FINDINGS: We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91–23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05–10•69), and age over 40 (aOR=1•36, 95%CI=1•07–1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001). INTERPRETATION: The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection. FUNDING: This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033).
format Online
Article
Text
id pubmed-7864613
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78646132021-02-09 Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China Li, Zhongjie Guan, Xuhua Mao, Naiying Luo, Huiming Qin, Ying He, Na Zhu, Zhen Yu, Jianxing Li, Yu Liu, Jianhua An, Zhijie Gao, Wenjing Wang, Xiaoli Sun, Xiaodong Song, Tie Yang, Xingfen Wu, Ming Wu, Xianping Yao, Wenqing Peng, Zhibin Sun, Junling Wang, Liping Guo, Qing Xiang, Nijuan Liu, Jun Zhang, Bike Su, Xuemei Rodewald, Lance Li, Liming Xu, Wenbo Shen, Hongbing Feng, Zijian Gao, George F Lancet Reg Health West Pac Research Paper BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population. METHODS: We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay. FINDINGS: We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91–23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05–10•69), and age over 40 (aOR=1•36, 95%CI=1•07–1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001). INTERPRETATION: The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection. FUNDING: This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033). Elsevier 2021-02-05 /pmc/articles/PMC7864613/ /pubmed/33585828 http://dx.doi.org/10.1016/j.lanwpc.2021.100094 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Li, Zhongjie
Guan, Xuhua
Mao, Naiying
Luo, Huiming
Qin, Ying
He, Na
Zhu, Zhen
Yu, Jianxing
Li, Yu
Liu, Jianhua
An, Zhijie
Gao, Wenjing
Wang, Xiaoli
Sun, Xiaodong
Song, Tie
Yang, Xingfen
Wu, Ming
Wu, Xianping
Yao, Wenqing
Peng, Zhibin
Sun, Junling
Wang, Liping
Guo, Qing
Xiang, Nijuan
Liu, Jun
Zhang, Bike
Su, Xuemei
Rodewald, Lance
Li, Liming
Xu, Wenbo
Shen, Hongbing
Feng, Zijian
Gao, George F
Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title_full Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title_fullStr Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title_full_unstemmed Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title_short Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
title_sort antibody seroprevalence in the epicenter wuhan, hubei, and six selected provinces after containment of the first epidemic wave of covid-19 in china
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864613/
https://www.ncbi.nlm.nih.gov/pubmed/33585828
http://dx.doi.org/10.1016/j.lanwpc.2021.100094
work_keys_str_mv AT lizhongjie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT guanxuhua antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT maonaiying antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT luohuiming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT qinying antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT hena antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT zhuzhen antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT yujianxing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT liyu antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT liujianhua antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT anzhijie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT gaowenjing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT wangxiaoli antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT sunxiaodong antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT songtie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT yangxingfen antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT wuming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT wuxianping antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT yaowenqing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT pengzhibin antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT sunjunling antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT wangliping antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT guoqing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT xiangnijuan antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT liujun antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT zhangbike antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT suxuemei antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT rodewaldlance antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT liliming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT xuwenbo antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT shenhongbing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT fengzijian antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina
AT gaogeorgef antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina